Arizona State Retirement System Buys 1,446 Shares of Moderna, Inc. (NASDAQ:MRNA)

Arizona State Retirement System grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 94,859 shares of the company’s stock after acquiring an additional 1,446 shares during the quarter. Arizona State Retirement System’s holdings in Moderna were worth $3,944,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Intrinsic Value Partners LLC boosted its holdings in Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after acquiring an additional 24,505 shares in the last quarter. Banco Santander S.A. bought a new position in shares of Moderna during the third quarter valued at $3,550,000. John G Ullman & Associates Inc. lifted its holdings in shares of Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after purchasing an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after purchasing an additional 167,596 shares in the last quarter. Finally, abrdn plc lifted its holdings in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 3.8 %

Shares of MRNA opened at $35.61 on Friday. The business has a 50-day simple moving average of $36.60 and a two-hundred day simple moving average of $49.03. The stock has a market cap of $13.74 billion, a price-to-earnings ratio of -3.84 and a beta of 1.86. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MRNA. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a report on Friday, February 14th. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Morgan Stanley lowered their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Finally, Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.